<sub id="pfpd9"><dfn id="pfpd9"></dfn></sub>

<address id="pfpd9"><var id="pfpd9"></var></address>
<sub id="pfpd9"><var id="pfpd9"></var></sub>

<thead id="pfpd9"><var id="pfpd9"><ins id="pfpd9"></ins></var></thead>

<address id="pfpd9"><listing id="pfpd9"></listing></address>

<sub id="pfpd9"><dfn id="pfpd9"></dfn></sub>

<sub id="pfpd9"><dfn id="pfpd9"></dfn></sub>

    <thead id="pfpd9"><var id="pfpd9"><output id="pfpd9"></output></var></thead><sub id="pfpd9"><var id="pfpd9"><ins id="pfpd9"></ins></var></sub><sub id="pfpd9"></sub>
    <address id="pfpd9"></address><address id="pfpd9"></address>

    <sub id="pfpd9"><dfn id="pfpd9"></dfn></sub>

      In the Pipeline

      Our pipeline is focused on therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients.

      Our Pipeline at a Glance as of August 29, 2019


      Compounds in Development


      We are transforming the way serious diseases are treated. Our pipeline currently has 37 compounds in development, focused on key therapeutic areas.

      Immuno-Oncology Interactive Pipeline

      See why effector cells are at the center of our research universe.

      Disease Area?

      Click on the therapeutic areas to learn more.

      In the Pipeline

      No filter applied. Showing 0 of 0 compounds.
      Sort By

      Generic Name /


      Brand Name
      Modality / Compound
      Disease Area
      Bristol-Myers Squibb continues development for HCV assets including Daklinza, Sunvepra and beclabuvir (NS5B Non Nuc) in select markets.
      Bristol-Myers Squibb maintains rights to additional assets being developed by Alliance Partners including Lirilumab.
      Please click on product name to see the Full U.S. Prescribing Information for ELIQUIS?, EMPLICITI?, NULOJIX?, OPDIVO?, ORENCIA?, SPRYCEL?, YERVOY?, including Boxed WARNINGS for ELIQUIS?, NULOJIX?, and Boxed WARNING for YERVOY? regarding immune-mediated adverse reactions.


      Phase I?– clinical trials investigating safety of an investigational medicine in a small number of human subjects.

      Phase II?– clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small number of patients who have the disease or condition under study.

      Phase III?– clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. For purposes of this chart, this includes the regulatory approval process prior to receiving marketing approval in the first major market.

      Marketed Product Development?– clinical trials investigating new uses or formulations regarding medicines that have already received regulatory approval for at least one indication in a major market.

      Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol-Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.